RxDoctor Payments Data

Daniel Rubin, MD

Cardiovascular Disease · Jefferson Hills, PANPI 1902862014

Payments from drug & device makers

$8,249in general payments, 2019–2025

Across 466 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$707
  • AstraZeneca$696
  • Amgen$634
  • Novartis$621
  • Pfizer$556
  • Boehringer Ingelheim$553
  • plus $4K from 29 others

What the payments were for

  • Food & beverage$8,20299%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,249 in reported general payments places this provider in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$86,437
Medicare patients
805
Services billed
1,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban407$401,447
Repatha SureclickEvolocumab133$97,204
XareltoRivaroxaban70$80,520
EntrestoSacubitril/Valsartan75$60,332
JardianceEmpagliflozin19$30,870
FarxigaDapagliflozin Propanediol12$8,791
Praluent PenAlirocumab11$7,074
Atorvastatin Calcium549$4,788
Diltiazem 24hr Er (Cd)Diltiazem Hcl193$4,172
Losartan Potassium530$3,961
Metoprolol Succinate336$3,653
Carvedilol567$2,511
Rosuvastatin Calcium192$1,960
Ranolazine ErRanolazine34$1,649
Icosapent Ethyl11$1,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$556$401,447407 claims
Johnson & JohnsonXarelto$707$80,52070 claims
NovartisEntresto$621$60,33275 claims
Boehringer IngelheimJardiance$553$30,87019 claims
AstraZenecaFarxiga$696$8,79112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Jefferson Hills

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →